Cargando…

Salvage focal brachytherapy in castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy

INTRODUCTION: Treatment strategy for castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy has not been established. CASE PRESENTATION: We described a case of castration‐resistant prostate cancer with neuroendocrine differentiation after initial external be...

Descripción completa

Detalles Bibliográficos
Autores principales: Komori, Takahiro, Kosaka, Takeo, Watanabe, Keitaro, Tanaka, Tomoki, Yasumizu, Yota, Hongo, Hiroshi, Mikami, Shuji, Ohashi, Toshio, Oya, Mototsugu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249630/
https://www.ncbi.nlm.nih.gov/pubmed/35795118
http://dx.doi.org/10.1002/iju5.12442
_version_ 1784739626395631616
author Komori, Takahiro
Kosaka, Takeo
Watanabe, Keitaro
Tanaka, Tomoki
Yasumizu, Yota
Hongo, Hiroshi
Mikami, Shuji
Ohashi, Toshio
Oya, Mototsugu
author_facet Komori, Takahiro
Kosaka, Takeo
Watanabe, Keitaro
Tanaka, Tomoki
Yasumizu, Yota
Hongo, Hiroshi
Mikami, Shuji
Ohashi, Toshio
Oya, Mototsugu
author_sort Komori, Takahiro
collection PubMed
description INTRODUCTION: Treatment strategy for castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy has not been established. CASE PRESENTATION: We described a case of castration‐resistant prostate cancer with neuroendocrine differentiation after initial external beam radiotherapy followed by salvage androgen deprivation therapy. Magnetic resonance imaging detected recurrence of a suspicious lesion in the left lobe of the prostate, although the prostate‐specific antigen level was <0.2 ng/mL. Transperineal prostate saturation needle biopsy detected adenocarcinoma with neuroendocrine differentiation. The patient underwent salvage focal brachytherapy and had a prostate‐specific antigen progression‐free survival of 20 months with no obvious adverse events. No recurrence has been detected on magnetic resonance imaging for 18 months. CONCLUSION: Salvage focal brachytherapy for prostate cancer after external beam radiotherapy can be one of the treatment strategies for local recurrence of castration‐resistant prostate cancer with neuroendocrine differentiation.
format Online
Article
Text
id pubmed-9249630
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-92496302022-07-05 Salvage focal brachytherapy in castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy Komori, Takahiro Kosaka, Takeo Watanabe, Keitaro Tanaka, Tomoki Yasumizu, Yota Hongo, Hiroshi Mikami, Shuji Ohashi, Toshio Oya, Mototsugu IJU Case Rep Case Reports INTRODUCTION: Treatment strategy for castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy has not been established. CASE PRESENTATION: We described a case of castration‐resistant prostate cancer with neuroendocrine differentiation after initial external beam radiotherapy followed by salvage androgen deprivation therapy. Magnetic resonance imaging detected recurrence of a suspicious lesion in the left lobe of the prostate, although the prostate‐specific antigen level was <0.2 ng/mL. Transperineal prostate saturation needle biopsy detected adenocarcinoma with neuroendocrine differentiation. The patient underwent salvage focal brachytherapy and had a prostate‐specific antigen progression‐free survival of 20 months with no obvious adverse events. No recurrence has been detected on magnetic resonance imaging for 18 months. CONCLUSION: Salvage focal brachytherapy for prostate cancer after external beam radiotherapy can be one of the treatment strategies for local recurrence of castration‐resistant prostate cancer with neuroendocrine differentiation. John Wiley and Sons Inc. 2022-04-28 /pmc/articles/PMC9249630/ /pubmed/35795118 http://dx.doi.org/10.1002/iju5.12442 Text en © 2022 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Case Reports
Komori, Takahiro
Kosaka, Takeo
Watanabe, Keitaro
Tanaka, Tomoki
Yasumizu, Yota
Hongo, Hiroshi
Mikami, Shuji
Ohashi, Toshio
Oya, Mototsugu
Salvage focal brachytherapy in castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy
title Salvage focal brachytherapy in castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy
title_full Salvage focal brachytherapy in castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy
title_fullStr Salvage focal brachytherapy in castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy
title_full_unstemmed Salvage focal brachytherapy in castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy
title_short Salvage focal brachytherapy in castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy
title_sort salvage focal brachytherapy in castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249630/
https://www.ncbi.nlm.nih.gov/pubmed/35795118
http://dx.doi.org/10.1002/iju5.12442
work_keys_str_mv AT komoritakahiro salvagefocalbrachytherapyincastrationresistantprostatecancerwithneuroendocrinedifferentiationafterradiationtherapy
AT kosakatakeo salvagefocalbrachytherapyincastrationresistantprostatecancerwithneuroendocrinedifferentiationafterradiationtherapy
AT watanabekeitaro salvagefocalbrachytherapyincastrationresistantprostatecancerwithneuroendocrinedifferentiationafterradiationtherapy
AT tanakatomoki salvagefocalbrachytherapyincastrationresistantprostatecancerwithneuroendocrinedifferentiationafterradiationtherapy
AT yasumizuyota salvagefocalbrachytherapyincastrationresistantprostatecancerwithneuroendocrinedifferentiationafterradiationtherapy
AT hongohiroshi salvagefocalbrachytherapyincastrationresistantprostatecancerwithneuroendocrinedifferentiationafterradiationtherapy
AT mikamishuji salvagefocalbrachytherapyincastrationresistantprostatecancerwithneuroendocrinedifferentiationafterradiationtherapy
AT ohashitoshio salvagefocalbrachytherapyincastrationresistantprostatecancerwithneuroendocrinedifferentiationafterradiationtherapy
AT oyamototsugu salvagefocalbrachytherapyincastrationresistantprostatecancerwithneuroendocrinedifferentiationafterradiationtherapy